期刊文献+

重组活化凝血因子Ⅶ和抑肽酶在肝移植术中的应用 被引量:2

Effects of recombinant factor Ⅶ (rFⅦa) and aprotinin in orthotopic liver transplantation.
原文传递
导出
摘要 目的 前瞻性地观察使用重组活化凝血因子Ⅶ(rFⅦa)和抑肽酶对减少肝移植术中出血的有效性和安全性。方法 将中山大学附属第三医院2003—2004年欲行肝移植60例病人术前随机分为3组,第1组为rFⅦa组,第2组为抑肽酶组,第3组为对照组。对3组病人各个时间点的凝血指标、凝血弹性图(TEG)指标进行观察,比较3组术中出血量、输血量、住院时间、住院费用和血管并发症。结果 使用rFⅦa后凝血酶原时间(PT)、TEG中的反应时间(R)和最大幅度(MA)与对照组差异有显著性(P〈0.05)。而部分凝血酶原时间(APTT)、纤维蛋白原水平(FIB)、血小板计数(PLT)和TEG中的血凝块减少速率(LY30)与对照组的差异无显著性(P〉0.05)。抑肽酶组与对照组MA和LY30的差异有显著性(P〈0.05),其他指标无明显改善。rFⅦa组和抑肽酶组术中出血量、输血量均较对照组明显减少(P〈0.05)。结论 rFⅦa能迅速改善外源性凝血系统功能,抑肽酶能改善新肝期的纤溶亢进,未见增加术后血管并发症。 Objective To evaluate the efficacy and safety of recombinant activated human coagulation factor Ⅶ (rFⅦa, NovoSeven) in orthotopic liver transPlantation. Methods Prospectively, sixty patients were randomized to rFVIIa treatment group aprotinin group and control group. Coagulation variables and thromboelastography (TEG) parameters [ reaction time (r),Clot lysis at 30 minutes (LY30%),and maximal amplitude (MA)] were recorded at described time points. Blood loss, transfusion requirements, hospital time, hospital cost and vascular complication were compared to controls. Results Administration of rFVIIa significantly shortened the prolonged prothrombin time (PT) and reaction time (r), increase maximal amplitude (MA) significantly ( P 〈 0. 05 ), whereas didn t influenced the activated partial thromboplastin time (APTF),fibrinogen (FIB),platelet count (PLT) and Clot lysis at 30 minutes (LY30%) (P 〉0. 05). Aprotinin group only increase maximal amplitude (MA) and decrease Clot lysis at 30 minutes ( LY30% ). In contrast with the control group, Both the perioperative blood loss and transfusion requirements were significantly reduced in rFVIIa group and aprotinin group ( P 〈0. 05). Conclusion This study demonstrated that rFⅦa rapidly improved the exogenous coagulation function,aprotinin slowly inhibits hyperfobrinolysis, Both of them obviously reduced operation bleeding, but never increased the postoperative vascular complications. Application of rFⅦa and aprotinin are effective and safe during orthotopic liver transplantation.
出处 《中国实用外科杂志》 CSCD 北大核心 2006年第1期45-47,共3页 Chinese Journal of Practical Surgery
基金 广东省自然科学资金资助(04105344)
关键词 肝移植 重组活化凝血因子Ⅶ 抑肽酶 Orthotopic liver transplantation Recombinant activated factor Ⅶ (rFⅦa) Aprotinin
  • 相关文献

参考文献8

  • 1Maddrey WC, Schiff ER, Sorrell ME, et al. Transplantation of the liver[M]. Lippincott Williams & Wilkins ,2001.1 -4.
  • 2Porte RJ,Knot EA, Bontempo FA. Hemostasis in liver transplantation [ J ]. Gastroenterology, 1989,97 (2) :488 - 496.
  • 3Roberts LR, Kamath PS, Pathophysiology and treatment of variceal hemorrhage[J]. Mayo Clin Prec, 1996,71 (10) :973 -983.
  • 4Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin - activatable fibrbrinolysis inhinbitor deficiency in cirrhosis is not associated with invreased plasma fibrinolysis [ J ]. Gastroenterology,2001,121 (1) :131 -139.
  • 5Kang Y. Transfusion based on clinical coagulation monitoring does reduce hemorrhage liver transplantation [ J ]. Liver Tansplant Surg, 1997,3 (6) :665,.
  • 6Hendriks HG, Meijer K, De Wolf JT, et al. Reduced transfusion requirements by recombinant factor Ⅶa in orthotopic liver transplantation : a pilot study [ J ]. Transplantation, 2001,71 ( 3 ) : 402- 405.
  • 7Lusher J, Ingerslev J, Roberts H, et al. Clinical experience with recombinant factor Ⅶa [ J ]. Blood Coagul Fibrinolysis, 1998,9(2) :119 -123.
  • 8Despotis GJ, Alsouflev A, Goodnough LT,et al. Aprotinin prolongs whole blood prothrombin time in patients undergoing cardiac surgery[ J ]. Anesth Analg, 1995,81 (5) :919 - 924.

同被引文献34

  • 1吴亚夫,仇毓东,江春平,丁义涛.肝移植术后早期腹腔内出血的防治[J].肝胆外科杂志,2007,15(1):18-20. 被引量:8
  • 2低血容量休克复苏指南(2007)[J].中国实用外科杂志,2007,27(8):581-587. 被引量:233
  • 3Kastner ES,Figueroa R,Garry D,et al.Emergency peripartum hysterectomy:experience at a community teaching hospital.Obstet Gynecol,2002,99:971-975.
  • 4Smith J,Mousa HA.Peripartum hysterectomy for primary postpartum haemorrhage:incidence and maternal morbidity.J Obstet Gynaecol,2007,27:44-47.
  • 5Roddie PH,Ludlam CA.Recombinant coagulation factors.Blood Rev,1997,11:169-177.
  • 6Mariani G,Lapecorella M,Dolce A.Steps towards an effective treatment strategy in congenital factor Ⅶ deficiency.Semin Hematol,2006,43:S42-S47.
  • 7White GC 2nd.Congenital and acquired platelet disorders:current dilemmas and treatment strategies.Semin Hematol,2006,43:S37-S41.
  • 8Kenet G,Walden R,Eldad A,et al.Treatment of traumatic bleeding with recombinant factor Ⅶ a.Lancet,1999,354:1879.
  • 9Franchini M,Zaffanello M,Veneri D.Recombinant factor Ⅶ a.An update on its clinical use.Thromb Haemost,2005,93:1027-1035.
  • 10MacLaren R,Weber LA,Brake H,et al.A multicenter assessment of recombinant factor Ⅶ a off-label usage:clinical experiences and associated outcomes.Transfusion,2005,45:1434-1442.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部